Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics

Abstract

Cell-free hemoglobin (Hb) is a driver of disease progression in conditions with intravascular or localized hemolysis. Genetic and acquired anemias or emergency medical conditions such as aneurysmal subarachnoid hemorrhage involve tissue Hb exposure. Haptoglobin (Hp) captures Hb in an irreversible protein complex and prevents its pathophysiological contributions to vascular nitric oxide depletion and tissue oxidation. Preclinical proof-of-concept studies suggest that human plasma-derived Hp is a promising therapeutic candidate for several Hb-driven diseases. Optimizing the efficacy and safety of Hb-targeting biotherapeutics may require structural and functional modifications for specific indications. Improved Hp variants could be designed to achieve the desired tissue distribution, metabolism, and elimination to target hemolytic disease states effectively. However, it is critical to ensure that these modifications maintain the function of Hp. Using transient mammalian gene expression of Hp combined with co-transfection of the pro-haptoglobin processing protease C1r-LP, we established a platform for generating recombinant Hp-variants. We designed an Hpβ-scaffold, which was expressed in this system at high levels as a monomeric unit (mini-Hp) while maintaining the key protective functions of Hp. We then used this Hpβ-scaffold as the basis to develop an initial proof-of-concept Hp fusion protein using human serum albumin as the fusion partner. Next, a hemopexin-Hp fusion protein with bispecific heme and Hb detoxification capacity was generated. Further, we developed a Hb scavenger devoid of CD163 scavenger receptor binding. The functions of these proteins were then characterized for Hb and heme-binding, binding of the Hp–Hb complexes with the clearance receptor CD163, antioxidant properties, and vascular nitric oxide sparing capacity. Our platform is designed to support the generation of innovative Hb scavenger biotherapeutics with novel modes of action and potentially improved formulation characteristics, function, and pharmacokinetics.

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic and Policlinic for Internal Medicine
04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurosurgery
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Molecular Medicine
Life Sciences > Pharmaceutical Science
Life Sciences > Drug Discovery
Uncontrolled Keywords:Drug Discovery, Pharmaceutical Science, Molecular Medicine
Language:English
Date:2 August 2021
Deposited On:03 Dec 2021 06:39
Last Modified:15 Mar 2025 04:38
Publisher:American Chemical Society (ACS)
ISSN:1543-8384
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1021/acs.molpharmaceut.1c00433
PubMed ID:34292741
Project Information:
  • Funder: Uniscientia Foundation
  • Grant ID:
  • Project Title:
  • Funder: SNSF
  • Grant ID: 310030_197823
  • Project Title: Targeting hemoglobin toxicity to prevent secondary brain damage after subarachnoid hemorrhage
  • Funder: SNSF
  • Grant ID: 8220-025042
  • Project Title: Theoretical and Munerical Analysis of the Eigenfrequencies of an Annular Membrane with Exterior Fluid and Attached Cavity.
Download PDF  'Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics'.
Preview
  • Content: Published Version
  • Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
8 citations in Web of Science®
8 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

47 downloads since deposited on 03 Dec 2021
8 downloads since 12 months
Detailed statistics

Authors, Affiliations, Collaborations

Similar Publications